Literature DB >> 33352062

Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies.

Niraj Kumar Jha1, Ankur Sharma2, Saurabh Kumar Jha1, Shreesh Ojha3, Dinesh Kumar Chellappan4, Gaurav Gupta5, Kavindra Kumar Kesari6, Shanu Bhardwaj7, Shakti D Shukla8, Murtaza M Tambuwala9, Janne Ruokolainen6, Kamal Dua8,10,11, Sandeep Kumar Singh12,13.   

Abstract

Excessive exposure to toxic substances or chemicals in the environment and various pathogens, including viruses and bacteria, is associated with the onset of numerous brain abnormalities. Among them, pathogens, specifically viruses, elicit persistent inflammation that plays a major role in Alzheimer's disease (AD) as well as dementia. AD is the most common brain disorder that affects thought, speech, memory and ability to execute daily routines. It is also manifested by progressive synaptic impairment and neurodegeneration, which eventually leads to dementia following the accumulation of Aβ and hyperphosphorylated Tau. Numerous factors contribute to the pathogenesis of AD, including neuroinflammation associated with pathogens, and specifically viruses. The human immunodeficiency virus (HIV) is often linked with HIV-associated neurocognitive disorders (HAND) following permeation through the blood-brain barrier (BBB) and induction of persistent neuroinflammation. Further, HIV infections also exhibited the ability to modulate numerous AD-associated factors such as BBB regulators, members of stress-related pathways as well as the amyloid and Tau pathways that lead to the formation of amyloid plaques or neurofibrillary tangles accumulation. Studies regarding the role of HIV in HAND and AD are still in infancy, and potential link or mechanism between both is not yet established. Thus, in the present article, we attempt to discuss various molecular mechanisms that contribute to the basic understanding of the role of HIV-associated neuroinflammation in AD and HAND. Further, using numerous growth factors and drugs, we also present possible therapeutic strategies to curb the neuroinflammatory changes and its associated sequels.

Entities:  

Keywords:  Alzheimer's disease; HAND; HIV; microglia; neuroinflammation; neurotherapeutics

Year:  2020        PMID: 33352062      PMCID: PMC7776571          DOI: 10.1098/rsob.200286

Source DB:  PubMed          Journal:  Open Biol        ISSN: 2046-2441            Impact factor:   6.411


  254 in total

1.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 2.  HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology.

Authors:  Diane M Lawrence; Eugene O Major
Journal:  Microbes Infect       Date:  2002-03       Impact factor: 2.700

Review 3.  Neuropsychiatric manifestations of HIV infection and AIDS.

Authors:  Benoit Dubé; Tami Benton; Dean G Cruess; Dwight L Evans
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

Review 4.  Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies.

Authors:  Niraj Kumar Jha; Saurabh Kumar Jha; Renu Sharma; Dhiraj Kumar; Rashmi K Ambasta; Pravir Kumar
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Neurocognitive effects of HIV, hepatitis C, and substance use history.

Authors:  Kathryn N Devlin; Assawin Gongvatana; Uraina S Clark; Jesse D Chasman; Michelle L Westbrook; Karen T Tashima; Bradford Navia; Ronald A Cohen
Journal:  J Int Neuropsychol Soc       Date:  2011-12-02       Impact factor: 2.892

6.  Insulin-like growth factor I (IGF-I) and IGF-binding protein 3 response to growth hormone is impaired in HIV-infected children.

Authors:  Mariangela Rondanelli; Desiree Caselli; Maurizio Aricò; Anna Maccabruni; Barbara Magnani; Luisa Bacchella; Anna De Stefano; Mohamed Maghnie; Sebastiano Bruno Solerte; Lorenzo Minoli
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-20       Impact factor: 2.205

Review 7.  Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring.

Authors:  Michael D Boska; R Lee Mosley; Mehmood Nawab; Jay A Nelson; Marina Zelivyanskaya; Larisa Poluektova; Mariano Uberti; Huanyu Dou; Travis B Lewis; Howard E Gendelman
Journal:  Curr HIV Res       Date:  2004-01       Impact factor: 1.581

8.  Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN.

Authors:  Muhammad Mukhtar; Steve Harley; Peiqin Chen; Mohammed BouHamdan; Charvi Patel; Edward Acheampong; Roger J Pomerantz
Journal:  Virology       Date:  2002-05-25       Impact factor: 3.616

9.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

Review 10.  The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

Authors:  Lavanya Varatharajan; Sarah A Thomas
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

View more
  4 in total

1.  HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent kinase II activation.

Authors:  Matheus F Sathler; Michael J Doolittle; James A Cockrell; India R Nadalin; Franz Hofmann; Sue VandeWoude; Seonil Kim
Journal:  J Cell Sci       Date:  2022-06-21       Impact factor: 5.235

2.  Signatures of somatosensory cortical dysfunction in Alzheimer's disease and HIV-associated neurocognitive disorder.

Authors:  Chloe C Casagrande; Alex I Wiesman; Mikki Schantell; Hallie J Johnson; Sara L Wolfson; Jennifer O'Neill; Craig M Johnson; Pamela E May; Susan Swindells; Daniel L Murman; Tony W Wilson
Journal:  Brain Commun       Date:  2022-06-23

Review 3.  Targeting autophagy in neurodegenerative diseases: From molecular mechanisms to clinical therapeutics.

Authors:  Amir Ajoolabady; Hamid Aslkhodapasandhokmabad; Nils Henninger; Laurie J Demillard; Masoud Nikanfar; Alireza Nourazarian; Jun Ren
Journal:  Clin Exp Pharmacol Physiol       Date:  2021-04-21       Impact factor: 2.963

Review 4.  CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.

Authors:  Shanu Bhardwaj; Kavindra Kumar Kesari; Mahesh Rachamalla; Shalini Mani; Ghulam Md Ashraf; Saurabh Kumar Jha; Pravir Kumar; Rashmi K Ambasta; Harish Dureja; Hari Prasad Devkota; Gaurav Gupta; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Janne Ruokolainen; Mohammad Amjad Kamal; Shreesh Ojha; Niraj Kumar Jha
Journal:  J Adv Res       Date:  2021-07-06       Impact factor: 12.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.